Eutilex.Co.Ltd Past Earnings Performance

Past criteria checks 0/6

Eutilex.Co.Ltd's earnings have been declining at an average annual rate of -8.8%, while the Biotechs industry saw earnings growing at 7.2% annually. Revenues have been declining at an average rate of 1.3% per year.

Key information

-8.8%

Earnings growth rate

2.2%

EPS growth rate

Biotechs Industry Growth11.7%
Revenue growth rate-1.3%
Return on equity-47.1%
Net Margin-798.1%
Last Earnings Update30 Jun 2024

Recent past performance updates

Recent updates

Despite Lacking Profits Eutilex.Co.Ltd (KOSDAQ:263050) Seems To Be On Top Of Its Debt

Aug 07
Despite Lacking Profits Eutilex.Co.Ltd (KOSDAQ:263050) Seems To Be On Top Of Its Debt

Is Eutilex.Co.Ltd (KOSDAQ:263050) A Risky Investment?

Apr 15
Is Eutilex.Co.Ltd (KOSDAQ:263050) A Risky Investment?

Could The Eutilex.Co.,Ltd. (KOSDAQ:263050) Ownership Structure Tell Us Something Useful?

Feb 05
Could The Eutilex.Co.,Ltd. (KOSDAQ:263050) Ownership Structure Tell Us Something Useful?

Revenue & Expenses Breakdown

How Eutilex.Co.Ltd makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

KOSDAQ:A263050 Revenue, expenses and earnings (KRW Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 243,035-24,22510,03413,812
31 Mar 24410-26,5499,40717,227
31 Dec 23132-27,7189,40918,504
30 Sep 23229-29,2339,22220,749
30 Jun 23252-32,9469,79323,174
31 Mar 23231-32,71210,47623,543
31 Dec 22216-33,42710,14224,640
30 Sep 22135-34,0189,61723,716
30 Jun 2295-29,2368,90123,032
31 Mar 2273-28,1928,25423,236
31 Dec 2174-29,5757,73324,155
30 Sep 211,211-29,4787,89525,133
30 Jun 211,255-31,3897,71624,425
31 Mar 211,963-32,9577,27621,750
31 Dec 202,036-28,7687,31218,219
30 Sep 20988-24,0677,28314,895
30 Jun 201,019-22,3017,98212,322
31 Mar 20405-18,5848,08510,986
31 Dec 19409-17,1317,9079,802
30 Sep 19412-17,0708,6348,249
30 Jun 19407-15,5629,6506,229
31 Mar 19404-14,1039,2135,206
31 Dec 18402-13,2337,7155,585
30 Sep 18389-11,6116,5815,279
30 Jun 18326-10,8794,6346,097
31 Mar 18231-10,3834,6525,261
31 Dec 17133-9,5935,6953,582

Quality Earnings: A263050 is currently unprofitable.

Growing Profit Margin: A263050 is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: A263050 is unprofitable, and losses have increased over the past 5 years at a rate of 8.8% per year.

Accelerating Growth: Unable to compare A263050's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: A263050 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (6.1%).


Return on Equity

High ROE: A263050 has a negative Return on Equity (-47.08%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies